Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults
Colchester Research Group, Canada.
PharmQuest, USA.
Canadian Phase Onward Inc, Canada.
Clinical Research Centre Sörmland.
Show others and affiliations
2024 (English)In: Vaccine: X, E-ISSN 2590-1362, Vol. 18, article id 100494Article in journal (Refereed) Published
Abstract [en]

Background: Previous phase 3 studies showed that the AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated lower respiratory tract disease in adults ≥ 60 years of age. This study evaluated lot-to-lot immunogenicity consistency, reactogenicity, and safety of three RSVPreF3 OA lots. Methods: This phase 3, multicenter, double-blind study randomized (1:1:1) participants ≥ 60 years of age to receive one of three RSVPreF3 OA lots. Serum RSVPreF3-binding immunoglobulin G (IgG) concentration was assessed at baseline and 30 days post-vaccination. Lot-to-lot consistency was demonstrated if the two-sided 95 % confidence intervals (CIs) of the RSVPreF3-binding IgG geometric mean concentration (GMC) ratios between each lot pair at 30 days post-vaccination were within 0.67 and 1.50. Solicited adverse events (AEs) within four days, unsolicited AEs within 30 days, and serious AEs (SAEs) and potential immune-mediated diseases within six months post-vaccination were recorded. Results: A total of 757 participants received RSVPreF3 OA, of whom 708 were included in the per-protocol set (234, 237, and 237 participants for each lot). Lot-to-lot consistency was demonstrated: GMC ratios were 1.06 (95 % CI: 0.94–1.21), 0.92 (0.81–1.04), and 0.87 (0.77–0.99) between the lot pairs (lot 1/2; 1/3; 2/3). For the three lots, the RSVPreF3-binding IgG concentration increased 11.84-, 11.29-, and 12.46-fold post-vaccination compared to baseline. The reporting rates of solicited and unsolicited AEs, SAEs, and potential immune-mediated diseases were balanced between lots. Twenty-one participants reported SAEs; one of these–a case of atrial fibrillation–was considered by the investigator as vaccine-related. SAEs with a fatal outcome were reported for four participants, none of which were considered by the investigator as vaccine-related. Conclusion: This study demonstrated lot-to-lot immunogenicity consistency of three RSVPreF3 OA vaccine lots and indicated that the vaccine had an acceptable safety profile. ClinicalTrials.gov: NCT05059301. © 2024 GSK

Place, publisher, year, edition, pages
Elsevier, 2024. Vol. 18, article id 100494
Keywords [en]
Immunogenicity, Lot-to-lot consistency, Older adults, Prefusion F protein vaccine, Respiratory syncytial virus, Safety, immunoglobulin G, respiratory syncytial virus prefusion F protein vaccine, respiratory syncytial virus vaccine, unclassified drug, adult, aged, arthralgia, Article, atrial fibrillation, confidence interval, controlled study, double blind procedure, drug safety, erythema, fatigue, female, fever, follow up, headache, human, immunoglobulin blood level, lot to lot immunogenicity, male, middle aged, multicenter study, myalgia, pain, phase 3 clinical trial, randomized controlled trial, respiratory syncytial virus infection, swelling, vaccination, vaccine immunogenicity, very elderly
National Category
Public Health, Global Health, Social Medicine and Epidemiology Geriatrics
Identifiers
URN: urn:nbn:se:bth-26212DOI: 10.1016/j.jvacx.2024.100494ISI: 001239248100001Scopus ID: 2-s2.0-85192251655OAI: oai:DiVA.org:bth-26212DiVA, id: diva2:1859275
Available from: 2024-05-21 Created: 2024-05-21 Last updated: 2024-06-19Bibliographically approved

Open Access in DiVA

fulltext(2857 kB)79 downloads
File information
File name FULLTEXT01.pdfFile size 2857 kBChecksum SHA-512
3dc9b2faa3933e13ef8e87006a409f2f8cff057b9de004fe34dc1ebdfe0c6935617186ff86b71bc3ceff6a55095b12cec2732a62c6c915ff94a4eb27ba65bc4d
Type fulltextMimetype application/pdf

Other links

Publisher's full textScopus

Authority records

Sanmartin Berglund, Johan

Search in DiVA

By author/editor
Sanmartin Berglund, Johan
By organisation
Department of Health
In the same journal
Vaccine: X
Public Health, Global Health, Social Medicine and EpidemiologyGeriatrics

Search outside of DiVA

GoogleGoogle Scholar
Total: 79 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 329 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf